Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Yahoo Finance
- Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure Yahoo Finance
- Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF Yahoo Finance
- SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity TCTMD
- Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free Reuters.com
- Ozempic could prevent diabetes. Should it be used for that? The Seattle Times